Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II controlled trial of combined immunotherapy with autologous effector lymphocytes in follicular non-Hodgkin lymphoma patients on rituximab maintenance after response to first-line chemotherapy
2009-017829-19Phase 2Completed
- Sponsor
- Cima Universidad de Navarra
- Start
- Dec 2009
- Countries
- 1
01
Overview
Phase 2 trial of lymphokine-activated killer cells in follicular lymphoma (FL) (2 arms), sponsored by Cima Universidad de Navarra. Primary endpoints: progression-free survival and safety. Started Dec 2009; status: completed.
02
Drugs
lymphokine-activated killer cells
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2009-017829-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017829-19.